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Abstract
Background: Resistance to anticancer agents is a major obstacle for successful chemotherapy in tongue squamous
cancer. Sam68 is an oncogenic-related protein in oral tongue squamous cell carcinoma functions as a signaling
molecule mediating apoptosis, whose over-expression is associated with the clinicopathologic characteristics and
prognosis of patients. The present study was to examine the effect of Sam68 on chemotherapeutics-induced
apoptosis in oral tongue squamous cell carcinoma, and its clinical significance in oral tongue squamous cell
carcinoma progression.
Methods: The effect of Sam68 on apoptosis induced by cisplatin was examined both in vitro and in vivo, using
Annexin V staining and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assays. Real-time
PCR and Western blotting analysis were used to detect mRNA and protein expression levels.
Results: Upregulation of Sam68 significantly inhibited cisplatin-induced apoptosis in oral tongue squamous cell
carcinoma cells, associated with induction of anti-apoptotic proteins caspase-9, caspase-3, and PARP. In contrast,
Silencing Sam68 expression significantly enhanced the sensitivity of oral tongue squamous cell carcinoma cells
to apoptosis induced by cisplatin both in vitro and in vivo.
Conclusions: The current study suggests that Sam68 could enhance the anti-apoptosis activity of oral tongue
squamous cell carcinoma cells. Sam68 is a potential pharmacologic target for the treatment of oral tongue
squamous cell carcinoma and inhibition of Sam68 expression might represent a novel strategy to sensitize
oral tongue squamous cell carcinoma to chemotherapy.
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Background
Worldwide, approximately 263,900 cases of oral cancer
are diagnosed each year, making oral cancer the 10th
most commonly diagnosed cancer in men. The most
common pathological type of oral tongue cancer is
squamous cell carcinoma [1]. The tongue is the most
cancer-prone intra-oral site in most populations [2].
Despite advances in standard treatment strategies (e.g.,
surgery, chemotherapy, and radiotherapy), the mortality
rate in patients with OTSCC has remained largely
unchanged for decades, with a 5-year survival rate of
approximately 50 % [3]. The 5-year survival rate for
patients with tongue cancer is 78 % for cancer exhibiting
local spread, 63 % for cancer exhibiting regional spread,
and 36 % for cancer exhibiting distant spread according
to the American Cancer Society [4, 5].
Cisplatin-based chemotherapy (DDP), as a common
standard therapeutic approach, plays an important role
in tongue cancer treatment and results in many thera-
peutic benefits, including reducing tumor size, inhibiting
the formation of distant metastatic lesions, and prolong-
ing patient survival [6]. Resistance to anticancer agents
is a major challenge for achieving successful chemother-
apy in tongue cancer and can result in more aggressive
tumor behavior and poor clinical outcomes [7, 8]. The
molecular basis of resistance to chemotherapy is com-
plex and involves various biological processes, such as
drug transport, drug metabolism, apoptosis, and DNA
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repair [9]. Although the mechanisms of resistance in
cancer have been extensively studied for decades, little is
known about the clinical causes of drug resistance. In
order to overcome drug resistance in tongue cancer
treatment, it will be necessary to clarify the mechanisms
of drug resistance and explore alternative therapeutic
strategies.
Src-associated protein in mitosis (Sam68, 68 kDa), a
member of the signal transduction and activation of
RNA (STAR) family, has been identified as an oncogenic
protein [10]. The function of Sam68 can be attributed to
its RNA-binding properties, through which Sam68 regu-
lates metabolism, nuclear export, and RNA stability.
Emerging evidence has suggested that Sam68 functions
as a signaling molecule in multiple signaling pathways
[11]. In particular, a recent study showed that Sam68
functions in both nuclear factor kappaB (NF-kB) activa-
tion and apoptosis initiated through the tumor necrosis
factor (TNF) receptor [12]. In a previous study, we
found that Sam68 is overexpressed in OTSCC and is
significantly associated with the clinicopathological
characteristics and prognosis of patients [13]. Nonethe-
less, the relationship between Sam68 overexpression and
the biological behaviors of human OTSCC remain
unexplored.
Therefore, in this study, we investigated the relation-
ship between Sam68 status and responses to chemo-
therapy both in vitro and in vivo and evaluated the
predictive value of Sam68 expression in OTSCC cell




Two human OTSCC cell lines, i.e., SCC-9 and SCC-
25, were obtained from the American Type Culture
Collection (ATCC, Manassas, VA, USA). Cells were
cultured in Dulbecco’s modified Eagle medium (Invitro-
gen, Carlsbad, CA, USA) supplemented with 10 % fetal
bovine serum (HyClone). Cells were grown in a 5 % CO2
humidified atmosphere at 37 °C.
Plasmids and transfection
A Sam68 overexpression construct was generated by
subcloning of polymerase chain reaction (PCR)-ampli-
fied full-length human Sam68 cDNA into the pMSCV
plasmid. For depletion of Sam68, two human Sam68-
targeting siRNA sequences were cloned into the pSuper-
retro-puro plasmid to generate pSuper-retro-Sam68-
RNAi(s). The sequences were as follows (synthesized by
Invitrogen): RNAi#1: GGACCACAAGGGAATACAATC;
RNAi#2: GCATCCAGAGGATACCTTTGC (5′ to 3′).
Retroviral production and infection were performed as
described previously [14]. Stable cell lines expressing
Sam68 or Sam68 shRNAs were selected for 10 days with
0.5 μg/mL puromycin.
RNA extraction, reverse transcription, and real-time PCR
Total RNA was extracted from cultured cells using TRI-
zol reagent (Invitrogen) according to the manufacturer’s
instructions. cDNAs were amplified and quantified using
an ABI Prism 7500 Sequence Detection System (Applied
Biosystems, Foster City, CA, USA) with SYBR Green I
dye (Molecular Probes, Eugene, OR, USA). Expression
data were normalized to the geometric mean of the
housekeeping gene β-actin. The primers were selected as
follows:
Sam68, forward 5′-ATGAAGCTTATGGCCAGGAC-3′
and reverse 5′-CAGAAGCCAGAATGCAGAGT-3′, β-
actin, forward 5′-TGGCACCCAGCACAATGAA-3′ and
reverse 5′-CTAAGTCATAGTCCGCCTAGAAGCA-3′.
Real-time PCR was performed according to standard
methods, as described previously [13].
Western blotting
Western blotting was performed according to standard
methods, as described previously,12 using polyclonal
rabbit anti-Sam68 antibodies (sc-733; Santa Cruz Bio-
technology, Santa Cruz, CA, USA), anti-caspase-9, anti-
cleaved caspase-9, anti-caspase-3, anti-cleaved caspase-3,
anti-poly (ADP-ribose) polymerase (PARP), and anti-
cleaved PARP antibodies (Cell Signaling Technology,
Danvers, MA, USA). The membranes were stripped and
reprobed with an anti-β-actin antibody (Sigma, St. Louis,
MO, USA) as a loading control.
Cell growth assay
The cell growth rates of cells with different levels of
Sam68 expression were determined by 2,3-bis-(2-meth-
oxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-car-boxani-
lide(XTT) assays. Cells were seeded into 96-well plates
at a density of 1 × 103 cells/well. The XTT kit (Sigma)
was used according to the manufacturer’s instruction.
Triplicate independent experiments were performed.
Terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) assays
The DeadEnd Fluorometric TUNEL system (Promega,
Madison, WI, USA) was used for TUNEL assays accord-
ing to the manufacturer’s instructions. A total of 3 × 104
cells were seeded on coverslips (Fisher Scientific) in 24-
well plates. After 24 h, all cells were incubated with cis-
platin, washed once with cold phosphate-buffered saline
(PBS), and fixed in freshly prepared 4 % formaldehyde
solution in PBS (pH 7.4) for 25 min at 4 °C. The fixed
slides were washed with PBS for 5 min and then perme-
abilized with 0.2 % Triton X-100 solution in PBS for
5 min. After a 5-min wash with PBS, and cells were
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covered with 100 μL Equilibration Buffer for 5 min. Cells
were then incubated for 60 min at 37 °C to terminate
the reaction and then washed in PBS for 5 min. The
samples were then stained in the dark with 1 μg/mL
propidium iodide (PI) solution for 15 min. After a final
wash with H2O for 5 min at ambient temperature and
air drying, samples were immediately analyzed under a
fluorescence microscope using a standard fluorescein fil-
ter set to view the green fluorescence of fluorescein at
520 nm and the red fluorescence of PI at 620 nm.
Annexin-V binding assay
An ApopNexin FITC Apoptosis Detection Kit (Milli-
pore, Lake Placid, NY, USA) was used to examine apop-
totic cells according to the manufacturer’s instructions.
A total of 3 × 105 cells were seeded in triplicate in 6-well
plates. After 24 h, all cells were incubation with cisplatin,
followed by washes with PBS and then the Annexin-V
binding solution. Subsequently, 150 μL of the Annexin-
V antibody in Binding Buffer was added to each culture
well. Cells were incubated for 15 min, 1.5 μL of PI was
added at 1 mg/mL, and cells were further incubated for
5 min. A total of 10,000 cells were analyzed on a flow
cytometer (FACSCalibur; BD Biosciences).
Xenograft tumor model in vivo
Female BALB/c nude mice (4–5 weeks of age, 18–20 g)
were purchased from the Center of Experimental Animals
of Guangzhou University of Chinese Medicine and were
housed in barrier facilities on a 12-h light/dark cycle. All
animal work was performed under the approval of the
Institutional Animal Care and Use Committee of Sun
Yat-sen University. BALB/c nude mice were randomly
divided into four groups (n = 10/group). For tumor cell
implantation, two groups of the mice were inoculated sub-
cutaneously with the SCC-9/vector and SCC-9/scramble
cells (1 × 106 per mouse, suspended in 100 μL sterile PBS)
in the right oxter as control groups. The other two groups
were inoculated with SCC-9/Sam68 and SCC-9/Sam68
RNAi#1 cells (1 × 106 per mouse, suspended in 100 μL
sterile PBS). Tumors were examined twice weekly; length,
width, and thickness measurements were obtained with
calipers, and tumor volumes were calculated using the
equation (L ×W2)/2. When tumors reached a volume of
50–100 mm3, each group was randomly assigned to two
subgroups (n = 5/group), followed by intraperitoneal injec-
tion of 100 μL PBS or cisplatin (2.5 mg/kg) on days 0, 3, 7,
10, 14, 17, 21, and 24. On day 28, animals were eutha-
nized, and tumors were excised, weighed, and subjected
to pathological examination.
Statistical analysis
All statistical analyses were carried out using the SPSS
17.0 statistical software package. Comparisons between
groups for statistical significance were performed with a
two-tailed paired Student’s t test. The χ2 test was used to
analyze the relationship between Sam68 expression and
clinicopathological characteristics. Survival curves were
Fig. 1 RT-PCR (a, c) and Western blotting (b, d) showed that Sam68 was highly expressed in Sam68-overexpressing cells relative to that in scramble
and blank vector control cells after 4 days of culture. Conversely, Sam68 was downregulated in Sam68-silenced cells relative to that in scramble and
blank vector control cells after 4 days of culture. β-actin expression was used as control
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plotted using the Kaplan-Meier method and compared
by the log-rank test. Survival data were evaluated using
univariate and multivariate Cox regression analyses. Dif-
ferences with P values of less than 0.05 were considered
statistically significant in all cases.
Results
Constructing stable Sam68 expression cell lines
Two OTSCC cell lines, SCC-9 and SCC-25, were con-
structed to stably overexpress Sam68, producing SCC-9/
Sam68 and SCC-25/Sam68 cells, or to stably silence
Sam68, producing SCC-9/shSam68 and SCC-25/shSam68
cells. SCC-9/vector, SCC-9/scramble, SCC-25/vector, and
SCC-25/scramble were used as control cells. Western
blotting and reverse transcription (RT)-PCR were used to
test Sam68 expression (Fig. 1). The results showed that
Sam68 was highly expressed in Sam68-overexpressing
cells relative to that in scramble and blank vector control
cells after 4 days of culture. Conversely, Sam68 was down-
regulated in Sam68-silenced cells relative to that in scram-
ble and blank vector control cells after 4 days of culture.
As a control, β-actin expression was not altered.
Dysregulation of Sam68 altered apoptosis in OTSCC cells
To further elucidate and characterize the anti-apoptotic
activity of Sam68 in OTSCC cells, in vitro studies were
performed using OTSCC cell lines with overexpression
or silencing of Sam68. Annexin V-binding and TUNEL
assays showed that Sam68-overexpressing SCC-9 and
SCC-25 cells exhibited significantly higher survival rates
than vector-control cells cultured under the same condi-
tions (Fig. 2). In contrast, the number of dead cells
markedly increased when Sam68 expression was silenced
by specific shRNA (Fig. 3).
Dysregulation of Sam68 altered the chemosensitivity of
OTSCC cells in vitro
To investigate whether Sam68 overexpression contrib-
uted to the chemoresistance of OTSCC cells, Sam68
overexpressing cells (SCC-9/Sam68). Sam68 silenced
cells (SCC-9/siRNA), and vector-control and scramble-
control cells respectively added platinum of different
concentration exhibited different survival rate. XTT
assays demonstrated that the survival rate of SCC-9/
Sam68 cells were more resistant to DDP than the
Fig. 2 Annexin V-binding (a) and TUNEL assays (b) showed that Sam68-overexpressing SCC-9 and SCC-25 cells exhibited significantly higher
survival rates than vector-control cells cultured under the same conditions
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vector-control and scramble-control cells. Additionally,
SCC-9/siRNA cells were more sensitive to DDP than
the vector-control and scramble-control cells (Fig. 4a).
Furthermore, the effects of Sam68 on apoptosis were
confirmed, as observed by increased activation of caspase
9, caspase 3, and PARP cleavage induced by DDP in cells
exhibiting different levels of Sam68 expression (Fig. 4b).
TUNEL assays showed that Sam68 upregulation conferred
resistance to OTSCC cells, and Sam68 downregulation
dramatically enhanced the sensitivity of these cells to
chemotherapeutics (Fig. 5).
Sam68 played an important anti-apoptotic role in OTSCC
in vivo
A panel of OTSCC cell lines was constructed to stably
express either Sam68 cDNA (SCC-9/Sam68) or Sam68
shRNA (SCC-9/Sam68 shRNA) and inoculated in nude
mice. Tumors derived from SCC-9/Sam68 cells grew
faster than tumors derived from the SCC-9/Sam68
shRNA cells. DDP blocked tumor growth, with highest
sensitivity in tumors derived from SCC-9/Sam68 shRNA
cells (Fig. 6a). After 28 days, the volumes and weights of
tumors formed by SCC-9/Sam68 cells were significantly
larger than those of tumors derived from vector-control
and scramble-control cells. In contrast, depletion of en-
dogenous Sam68 in SCC-9 cells caused significant inhib-
ition of tumor growth in terms of both tumor volume
and weight (Fig. 6b). TUNEL assays showed that cells
from tumors showing Sam68 upregulation exhibited
resistance to DDP, whereas cells derived from tumors
showing Sam68 downregulation exhibited dramatically
enhanced sensitivity to DDP (Fig. 7a).
Western blot analysis showed that tumors derived
from Sam68-overexpressing cells exhibited increased
activation of caspase 9 and PARP cleavage in response to
DDP (Fig. 7b).
Discussion
OTSCC is one of the most lethal malignancies of the di-
gestive tract in East Asian countries. Many cases are di-
agnosed after the malignancy has already reached an
advanced stage; thus, significant morbidity and mortality
are observed due to the disease and sequelae associated
with therapeutic management and complications [15, 16].
Though surgery remains the mainstay of treatment for re-
sectable disease, multimodal therapies are necessary to
prolong the survival of patients with OTSCC. Empiric
clinical trials have defined the standard first-line chemo-
therapeutic regimens and dosage to achieve optimal
therapeutic efficacy with acceptable safety in patients
with different types of tumors. The most common chemo-
therapy drugs used for advanced OTSCC are taxanes
(paclitaxel and docetaxel), anthracyclines (adriamycin,
epirubicin, and pirarubicin), platinum-based agents
Fig. 3 Annexin V-binding(c) and TUNEL assays (d) showed that Sam68 silenced SCC-9 and SCC-25 cells exhibited significantly lower survival rates
than Scramble cells cultured under the same conditions. But the survival rates between two samples of SCC-9 or SCC-25 had little difference
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(cisplatin and carboplatin), and antimetabolites (e.g.,
methotrexate and 5-fluorouracil). Platinum-containing
compounds, particularly cisplatin, target DNA to form
intrastrand and interstrand cross-links; this results in dis-
tortion of the DNA helix and apoptotic cell death. How-
ever, patients inevitably experience tumor progression or
relapses due to the acquisition of drug resistance or the
emergence of cell subpopulations genetically refractory to
the drugs [17, 18]. A couple of recent studies have re-
ported the role of unfavorable genetic variants and miR-
NAs in modulating chemoresistance [19–22].
In this study, we demonstrated, for the first time, that
Sam68 played a biological role in OTSCC progression
and chemotherapy resistance. Additionally, we found
Fig. 4 XTT assays demonstrated that the survival rate of SCC-9/Sam68 cells were more resistant to DDP than the vector-control and scramble-control
cells. Additionally, SCC-9/siRNA cells were more sensitive to DDP than the vector-control and scramble-control cells (a). Sam68 increase activation of
caspase 9, caspase 3, and PARP cleavage induced by DDP in cells exhibiting different levels of Sam68 expression (b)
Fig. 5 TUNEL assays was carried in two OTSCC cell lines, SCC-9 and SCC-25 (a, b) to test the anti-resistance and drug-resisstant. The results
showed that Sam68 upregulation conferred resistance to OTSCC cells Sam68 upregulation enhanced the resistance of these cells to chemothera-
peutics, DDP, and Sam68 downregulation dramatically enhanced the sensitivity of these cells to chemotherapeutics
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that overexpression of Sam68 enhanced anti-apoptotic
and drug resistance in OTSCC cell lines treated with
DDP. Thus, our findings provide important insights into
the role of Sam68 in OTSCC.
Drug resistance is predictable given the common pres-
ence of genomic instability in cancers, which can result
in the accumulation of multiple genetic aberrations, in-
cluding those that impact chemotherapy response signal-
ing [23–25]. Evandro Luís Niero et al. comprehensive
analysis to find that the resistance of CSCs to currently
used chemotherapeutics is a major contributing factor in
cancer recurrence and later metastasis development
appraise the experimental progress in the study of ac-
quired drug resistance of cancer cells in different models
[26]. Ryoichi Fujii et al. pointed that the certain Cox-2
inhibitors may inhibit EMT and lymph node metastasis
by restoring E-cadherin expression and down-regulating
of CDH-1 in head neck squamous cancer [27]. Zhou et
al. revealed miR-223/FBXW7may be a potential strategic
approach for reversing the DDP resistance in human
gastric carcinoma [28].
In a previous study, we found that Sam68 is overex-
pressed in OTSCC and that Sam68 is significantly asso-
ciated with the clinicopathological characteristics and
Fig. 6 Tumors derived from SCC-9/Sam68 cells grew faster than tumors derived from the vector-control and scramble-control cells. Oppositely
the SCC-9/Sam68 shRNA cells grew slowly than tumors derived from the vector-control and scramble-control cells. DDP blocked tumor growth
with highest sensitivity in tumors derived from SCC-9/Sam68 shRNA cells, but lowest sensitivity in tumors derived from SCC-9/Sam68 cells (a).
After 28 days culture, the volumes of tumors formed by SCC-9/Sam68 cells were significantly larger than those of tumors derived from vector-control
and scramble-control cells. In contrast, depletion of endogenous Sam68 in SCC-9 cells caused significant inhibition of tumor growth in volume (b)
Fig. 7 TUNEL assays showed that cells from tumors showing Sam68 upregulation exhibited resistance to DDP, whereas cells derived from tumors
showing Sam68 downregulation exhibited dramatically enhanced sensitivity to DDP (a). Western blot analysis showed that tumors derived from
Sam68-overexpressing cells exhibited increased activation of caspase 9 and PARP cleavage in response to DDP (b)
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prognosis of patients [13]. NF-kB signaling plays a vital
role in cell survival by upregulating gene products that
block apoptosis. Additionally, emerging evidence sug-
gests that Sam68 functions as a signaling molecule in
multiple signaling pathways [11], including NF-kB acti-
vation and apoptosis initiated through the TNF receptor
[12]. Consistent with this, our results showed that up-
regulation of Sam68 significantly inhibited cisplatin-
induced apoptosis in OTSCC cells and this effect was as-
sociated with induction of the anti-apoptotic proteins
caspase-9, caspase-3, and PARP. In contrast, silencing of
Sam68 expression significantly enhanced the sensitivity
of OTSCC cells to apoptosis induced by cisplatin both
in vitro and in vivo.
Conclusions
In summary, upregulation of Sam68 may reduce
cisplatin-induced apoptosis in OTSCC cells; however,
the underlying mechanism of acquired chemosensitivity
in Sam68-deficient cells is unclear. Further studies are
needed to elucidate these mechanisms. Using current
therapies, differentiated tumor cells die through apop-
tosis after platinum-induced DNA damage. Thus,
Sam68-mediated inhibition of apoptosis in Sam68-
negative tumor cells may facilitate DNA repair, thereby
promoting survival.
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